Hsbc Holdings PLC Invests $1.03 Million in Replimune Group, Inc. $REPL

Key Points

• HSBC Holdings initiated a $1.03 million position in Replimune Group, buying 92,154 shares, while institutional investors collectively own 92.53% of the company.
• Analyst sentiment is generally positive: Replimune has a consensus “Moderate Buy” rating and an average price target of $12, with recent upgrades from Wedbush, JPMorgan, and BMO Capital Markets.
• Replimune shares opened at $12.92, near their 50-day moving average, but the company reported a quarterly loss of $0.72 per share versus the $0.69 consensus estimate. Its lead candidate, RP1, is an investigational oncolytic immunotherapy for solid tumors.

Hsbc Holdings PLC bought a new stake in Replimune Group, Inc. (NASDAQ:REPL - Free Report) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 92,154 shares of the company's stock, valued at approximately $1,035,000. Hsbc Holdings PLC owned approximately 0.11% of Replimune Group as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently modified their holdings of the business. Wellington Management Group LLP lifted its holdings in Replimune Group by 9.0% during the second quarter. Wellington Management Group LLP now owns 215,302 shares of the company's stock worth $2,383,000 after acquiring an additional 17,724 shares during the period. Jefferies Financial Group Inc. bought a new position in Replimune Group in the 2nd quarter valued at $5,485,000. Bank of America Corp DE bought a new position in Replimune Group in the 2nd quarter valued at $3,646,000. ADAR1 Capital Management LLC bought a new position in Replimune Group in the 2nd quarter valued at $7,260,000. Finally, Legal & General Group Plc purchased a new stake in shares of Replimune Group during the 2nd quarter valued at $85,000. 92.53% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on REPL shares. Wedbush upgraded Replimune Group from a "neutral" rating to an "outperform" rating and set a $12.00 target price on the stock in a research note on Friday, August 7th. JPMorgan Chase & Co. increased their price target on shares of Replimune Group from $20.00 to $21.00 and gave the company an "overweight" rating in a research report on Wednesday, August 26th. Wall Street Zen upgraded shares of Replimune Group from a "strong sell" rating to a "sell" rating in a report on Saturday, May 23rd. Weiss Ratings lowered shares of Replimune Group from a "sell (d-)" rating to a "sell (e+)" rating in a research report on Tuesday, August 11th. Finally, BMO Capital Markets raised shares of Replimune Group from an "underperform" rating to an "outperform" rating and set a $16.00 target price for the company in a research report on Tuesday, June 30th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has given a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $12.00.

Insider Buying and Selling at Replimune Group

In related news, CEO Sushil Patel sold 39,341 shares of the company's stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $12.97, for a total transaction of $510,252.77. Following the sale, the chief executive officer directly owned 708,151 shares in the company, valued at approximately $9,184,718.47. This represents a 5.26% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Emily Hill sold 11,448 shares of the firm's stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $12.97, for a total transaction of $148,480.56. Following the completion of the transaction, the chief financial officer directly owned 225,108 shares of the company's stock, valued at approximately $2,919,650.76. This trade represents a 4.84% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 79,124 shares of company stock worth $1,038,364 over the last ninety days. Company insiders own 5.40% of the company's stock.

Replimune Group Price Performance

Shares of NASDAQ REPL opened at $12.92 on Monday. The company has a debt-to-equity ratio of 1.00, a current ratio of 5.23 and a quick ratio of 5.23. The stock has a market capitalization of $1.21 billion, a PE ratio of -4.10 and a beta of 0.94. Replimune Group, Inc. has a one year low of $1.50 and a one year high of $16.33. The business's fifty day moving average price is $12.53 and its 200-day moving average price is $8.82.

Replimune Group (NASDAQ:REPL - Get Free Report) last announced its quarterly earnings data on Friday, August 14th. The company reported ($0.72) earnings per share for the quarter, missing the consensus estimate of ($0.69) by ($0.03). On average, equities research analysts anticipate that Replimune Group, Inc. will post -2.81 EPS for the current year.

Replimune Group Profile

Replimune Group, Inc is a biotechnology company focused on developing oncolytic immunotherapies designed to stimulate the immune system to recognize and attack cancer. The company's approach is based on a proprietary platform that uses genetically engineered herpes simplex virus type 1 (HSV-1) to selectively replicate in tumors and deliver immune-activating payloads.

Replimune's lead product candidate is RP1, also known as vusolimogene oderparepvec, an investigational oncolytic immunotherapy being evaluated in clinical studies for solid tumors, including melanoma and cutaneous squamous cell carcinoma.

Want to see what other hedge funds are holding REPL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Replimune Group, Inc. (NASDAQ:REPL - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.